TherapeuticsMD (TXMD) Current Leases (2019 - 2020)
TherapeuticsMD's (TXMD) quarterly Current Leases came in at $2.3 million in Q4 2020, up 50.11% on a YoY basis from $1.5 million in Q1 2020, and down 6.25% quarter-over-quarter from $2.4 million in Q3 2020.
Powered by 
Analysis
TherapeuticsMD (TXMD) Current Leases (2019 - 2020) Analysis & Trends
TherapeuticsMD (TXMD) has reported Current Leases for 2 consecutive years, with $2.3 million the latest figure, recorded in Q4 2020.
- For the quarter ending Q4 2020, Current Leases rose 50.11% year-over-year to $2.3 million; the trailing twelve-month figure through Dec 2020 stood at $2.3 million (up 50.11% YoY), and the FY2020 full-year result was $2.3 million, up 50.11% from the prior year.
- Current Leases declined to $2.3 million in Q4 2020 per TXMD's latest filing, from $2.4 million in the prior quarter.
- Across five years, Current Leases topped out at $2.4 million in Q3 2020 and bottomed at $1.2 million in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 274.00 Mn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 263.86 Mn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 16.75 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 21.95 Mn |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 2.25 Mn |
| Sep 30, 2020 | 2.40 Mn |
| Jun 30, 2020 | 2.11 Mn |
| Mar 31, 2020 | 1.75 Mn |
| Dec 31, 2019 | 1.50 Mn |
| Sep 30, 2019 | 1.24 Mn |
| Mar 31, 2019 | 1.16 Mn |